Grace Therapeutics (NASDAQ:GRCE) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Grace Therapeutics (NASDAQ:GRCE) issued its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports.

Grace Therapeutics Trading Down 0.9 %

GRCE traded down $0.03 on Thursday, reaching $3.45. 13,053 shares of the company traded hands, compared to its average volume of 126,855. Grace Therapeutics has a 52-week low of $2.13 and a 52-week high of $4.97. The stock has a market cap of $34.98 million, a P/E ratio of -3.42 and a beta of 1.36. The business has a 50 day moving average price of $3.74.

About Grace Therapeutics

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.